EE405 A UK Cost-Minimisation Analysis of Brolucizumab Versus Aflibercept in Diabetic Macular Oedema (DMO)
Dec 1, 2022, 00:00
10.1016/j.jval.2022.09.651
https://www.valueinhealthjournal.com/article/S1098-3015(22)02855-8/fulltext
Title :
EE405 A UK Cost-Minimisation Analysis of Brolucizumab Versus Aflibercept in Diabetic Macular Oedema (DMO)
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(22)02855-8&doi=10.1016/j.jval.2022.09.651
First page :
Section Title :
Open access? :
No
Section Order :
10189